Get the Stockscreener App
98.66
0.19%
0.19
Pre-market:
96.86
-1.80
-1.82%
Guardant Health Inc stock is traded at $98.66, with a volume of 1.29M.
It is up +0.19% in the last 24 hours and up +14.19% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$98.47
Open:
$98.2
24h Volume:
1.29M
Relative Volume:
0.65
Market Cap:
$13.08B
Revenue:
$1.08B
Net Income/Loss:
$-433.19M
P/E Ratio:
-29.01
EPS:
-3.4004
Net Cash Flow:
$-225.09M
1W Performance:
+6.94%
1M Performance:
+14.19%
6M Performance:
+4.55%
1Y Performance:
+142.29%
1-Day Range:
$96.04
$99.54
1-Week Range:
$89.07
$100.73
52-Week Range:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
98.66 | 13.06B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
448.21 | 165.75B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
164.54 | 117.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
532.86 | 41.70B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
333.21 | 32.89B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
113.26 | 31.86B | 7.07B | 1.29B | 993.00M | 4.5355 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
The Cancer Test That Wall Street Is Betting On - WSJ
Guardant Health Insider Sold Shares Worth $5,016,000, According to a Recent SEC Filing - Moomoo
Guardant Health (GH) co-CEO family trust sells 50,000 shares - Stock Titan
Guardant Health co-CEO Talasaz sells $5.02 million in stock By Investing.com - Investing.com India
Guardant Health co-CEO Talasaz sells $5.02 million in stock - Investing.com
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Guardant Health (GH) Q1 2026 Earnings Transcript - AOL.com
Guardant Health CMO resigns - MSN
GH Q1 Deep Dive: Shield Volume Acceleration and Oncology Portfolio Expansion Fuel Growth - Yahoo Finance
Trading the Move, Not the Narrative: (GH) Edition - Stock Traders Daily
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health Insiders Sold US$52m Of Shares Suggesting Hesitancy - 富途牛牛
Guardant Health raises 2026 revenue outlook to $1.30B-$1.32B as Shield targets 230,000-245,000 tests - MSN
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $135 - Moomoo
Evercore ISI Keeps an “In Line” Rating on Guardant Health, Inc. (GH) - Insider Monkey
Guardant Health, Inc. (GH) Stock Analysis: Unveiling a 36% Upside Potential in Precision Oncology - DirectorsTalk Interviews
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen - Insider Monkey
Guardant Health, Inc. (NASDAQ:GH) Q1 2026 Earnings Call Transcript - Insider Monkey
Guardant Health (GH) Gets a Buy from Canaccord Genuity - The Globe and Mail
Guardant Health Q1 2026 slides: revenue soars 48% on Shield momentum By Investing.com - Investing.com South Africa
Guardant Health : Q1 2026 Earnings Call - marketscreener.com
GH Maintained by JP Morgan -- Price Target Raised to $135 - GuruFocus
GH Maintained by Barclays -- Price Target Raised to $120 - GuruFocus
Guardant Health (GH) Announces Departure of Chief Medical Officer - GuruFocus
Guardant Health, Inc. Q1 2026 Financial Results and Analysis – Revenue, Expenses, and Comprehensive Loss Overview - Minichart
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $95 to $135 - Moomoo
Guardant Health Q1 2026 slides: revenue soars 48% on Shield momentum - Investing.com Australia
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $120 - 富途牛牛
BofA Securities Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $135 - Moomoo
Guardant Health: Q1 Earnings Snapshot - theheraldreview.com
Guardant Health 1Q Loss/Shr 85c >GH - Moomoo
GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill
Earnings call transcript: Guardant Health Q1 2026 revenue soars, EPS misses By Investing.com - Investing.com South Africa
Earnings call transcript: Guardant Health Q1 2026 revenue soars, EPS misses - Investing.com Nigeria
Guardant Health Q1 Earnings Call Highlights - Barchart.com
Guardant Health, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:GH) 2026-05-07 - Seeking Alpha
GH Financials: Income Statement, Balance Sheet & Cash Flow | Guardant Health - Stock Titan
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics - Yahoo! Finance Canada
Research Alert: Guardant Health: Testing Volume Growth Highlights Successful Q1 Results - Moomoo
Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Guardant Health Stock Sinks After Surprise Share Sale - TipRanks
Guardant Health Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Guardant Health (NASDAQ:GH) Delivers Impressive Q1 CY2026, Stock Soars - Barchart.com
Guardant Health Q1 Adjusted Loss Narrows, Revenue Rises; Raises Full-Year Revenue Guidance - marketscreener.com
Guardant Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Guardant Health (GH) grows revenue to $302M while managing losses and legal battles - Stock Titan
(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.30B$1.32B, vs. FactSet Est of $1.27B - marketscreener.com
Guardant Health (NASDAQ:GH) Smashes Q1 Estimates, Raises Full-Year Guidance on Soaring Screening Revenue - ChartMill
Earnings Flash (GH) Guardant Health, Inc. Posts Q1 Adjusted Loss $0.45 per Share, vs. FactSet Est of $-0.45 - marketscreener.com
Earnings Flash (GH) Guardant Health, Inc. Reports Q1 Revenue $301.7M, vs. FactSet Est of $279.2M - marketscreener.com
Guardant Health (NASDAQ: GH) boosts 2026 revenue guidance on 48% Q1 jump - Stock Titan
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):